CA2897164A1 - Insulino-independance parmi des patients atteints du diabete a l'aide d'une combinaison de ppi in avec un agent de tolerance immunitaire - Google Patents

Insulino-independance parmi des patients atteints du diabete a l'aide d'une combinaison de ppi in avec un agent de tolerance immunitaire Download PDF

Info

Publication number
CA2897164A1
CA2897164A1 CA2897164A CA2897164A CA2897164A1 CA 2897164 A1 CA2897164 A1 CA 2897164A1 CA 2897164 A CA2897164 A CA 2897164A CA 2897164 A CA2897164 A CA 2897164A CA 2897164 A1 CA2897164 A1 CA 2897164A1
Authority
CA
Canada
Prior art keywords
diabetes
cells
beta
insulin
immune tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2897164A
Other languages
English (en)
Inventor
Claresa LEVETAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/662,253 external-priority patent/US9133440B2/en
Priority claimed from US13/662,245 external-priority patent/US9511110B2/en
Priority claimed from US13/662,209 external-priority patent/US8911776B2/en
Priority claimed from US13/662,232 external-priority patent/US20140120560A1/en
Application filed by Individual filed Critical Individual
Publication of CA2897164A1 publication Critical patent/CA2897164A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2897164A 2012-09-27 2013-09-26 Insulino-independance parmi des patients atteints du diabete a l'aide d'une combinaison de ppi in avec un agent de tolerance immunitaire Abandoned CA2897164A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261706225P 2012-09-27 2012-09-27
US61/706,225 2012-09-27
US13/662,245 2012-10-26
US13/662,253 US9133440B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,232 2012-10-26
US13/662,245 US9511110B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 US8911776B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 2012-10-26
US13/662,232 US20140120560A1 (en) 2012-10-26 2012-10-26 Generation of new pancreatic beta cells
US13/662,253 2012-10-26
US201361749197P 2013-01-04 2013-01-04
US61/749,197 2013-01-04
PCT/US2013/061972 WO2014052625A1 (fr) 2012-09-27 2013-09-26 Insulino-indépendance parmi des patients atteints du diabète à l'aide d'une combinaison de ppi in avec un agent de tolérance immunitaire

Publications (1)

Publication Number Publication Date
CA2897164A1 true CA2897164A1 (fr) 2014-04-03

Family

ID=50388970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2897164A Abandoned CA2897164A1 (fr) 2012-09-27 2013-09-26 Insulino-independance parmi des patients atteints du diabete a l'aide d'une combinaison de ppi in avec un agent de tolerance immunitaire

Country Status (3)

Country Link
AU (1) AU2013323476A1 (fr)
CA (1) CA2897164A1 (fr)
WO (1) WO2014052625A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106074602A (zh) * 2016-06-22 2016-11-09 深圳爱生再生医学科技有限公司 混合细胞制剂及其制备方法与应用
CN116332952A (zh) * 2021-12-15 2023-06-27 厦门大学 单端孢霉烯类、有机酸类、苯二氮卓类和生物碱类化合物及其在制备降血糖药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524268A1 (fr) * 2003-05-06 2004-11-18 Altana Pharma Ag Agents pour le traitement de troubles du bas-ventre
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
EP1706098A4 (fr) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc Systemes micellaires convenant pour l'apport de composes lipophiles ou hydrophobes
US20090042781A1 (en) * 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
SI2193142T1 (sl) * 2007-08-30 2015-05-29 Curedm Group Holdings, Llc Sestavek in postopek za uporabo proislet peptidov in analogov le-teh

Also Published As

Publication number Publication date
AU2013323476A1 (en) 2015-07-30
WO2014052625A1 (fr) 2014-04-03

Similar Documents

Publication Publication Date Title
Cayabyab et al. Advances in pancreatic islet transplantation sites for the treatment of diabetes
Levetan et al. Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes
Kolb et al. Immunotherapy for type 1 diabetes: why do current protocols not halt the underlying disease process?
Rangel Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug–drug interactions
EP3151853B1 (fr) La glutamate décarboxylase (gad) pour le traitement d'une maladie auto-immune
EP2941250A1 (fr) Insulino-indépendance parmi des patients atteints du diabète à l'aide d'une combinaison de ppi in avec un agent de tolérance immunitaire
CA2609667A1 (fr) Peptides, derives et analogues associes, et leurs methodes d'utilisation
Coppieters et al. The development of immunotherapy strategies for the treatment of type 1 diabetes
US20150174111A1 (en) Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
Ding et al. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice
CA2897164A1 (fr) Insulino-independance parmi des patients atteints du diabete a l'aide d'une combinaison de ppi in avec un agent de tolerance immunitaire
US20140234405A1 (en) Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
US8808689B1 (en) Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
US20180125933A1 (en) Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
WO2014153227A1 (fr) Procédés de préservation et de protection des cellules bêta pancréatiques et de traitement ou de prévention du diabète en inhibant nox-1
US20220088010A1 (en) Co-Administration of inhibitors to produce insulin producing gut cells
Bolla et al. Next-gen therapeutics to spare and expand beta-cell mass
Sena et al. Diabetes mellitus: new challenges and innovative therapies
US20200138920A1 (en) Novel Combinations for Antigen Based Therapy
Camhi et al. Treating Diabetes with islet transplantation: lessons from the University of Miami
Juang et al. Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice
George Future trends in diabetes management.
Casares et al. A Peptide-Major Histocompatibility Complex II Chimera Favors Survival of Pancreatic β-Ιslets Grafted in Type 1 Diabetic Mice
Wu et al. Novel Treatments and the Future of DKD: What Is on the Horizon?
Aggarwal Targeting Apoptosis and Necroptosis Inhibition to Improve Islet Graft Function

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180926